CellectisCMVLF 59 FCF Margin % is -271.33% as of Mar. 2026. GuruFocus rates CMVLF with a GF Score™ of 59/100 and a GF Value™ of $4.32 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 960 Biotechnology companies, Cellectis ranks better than 52.92% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cellectis's Free Cash Flow for the
three
months ended in Mar. 2026 was $-15.68 Mil. Cellectis's Revenue for the
three
months ended in Mar. 2026 was $5.78 Mil. Therefore, Cellectis's FCF Margin % for the quarter that ended in Mar. 2026 was -271.33%.
The historical rank and industry rank for Cellectis's FCF Margin % or its related term are showing as below:
CMVLF'
s FCF Margin % Range Over the Past 10 Years
Min: -3421.39 Med: -324.97 Max: 46.13
Current: -60.31
During the past 13 years, the highest FCF Margin % of Cellectis was 46.13%. The lowest was -3421.39%. And the median was -324.97%.
CMVLF's FCF Margin % is ranked better than 52.92% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs CMVLF: -60.31
Cellectis FCF Margin % Related Terms
Cellectis FCF Margin % Historical Data
* Premium members only.
The historical data trend for Cellectis's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMVLF vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Cellectis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectis FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectis's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cellectis's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectis (CMVLF) has a FCF Margin % of -271.33% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cellectis and its competitors. According to the industry distribution chart, Cellectis ranks #452 out of 960 companies in the Biotechnology industry, placing it in the top 47.1%.
Is Cellectis' FCF Margin % too high?
Cellectis' current FCF Margin % is -271.33%. Based on the distribution chart, Cellectis ranks #452 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cellectis has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cellectis ranks #452 out of 960 companies for FCF Margin %. This puts Cellectis in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cellectis and its competitors. Cellectis's current FCF Margin % is -271.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (CMVLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.32, compared to a current price of $3.47 — trading 19.7% below its estimated fair value. The current FCF Margin % is -271.33%. Cellectis' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cellectis (CMVLF), the current FCF Margin % is -271.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cellectis (CMVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Cellectis stock appears to be undervalued.
The current stock price of $3.47 is trading 19.7% below its estimated GF Value™ of $4.32.
GuruFocus considers Cellectis to be Modestly Undervalued.
Key valuation signals for CMVLF:
FCF Margin %: -271.33%
GF Value™: $4.32 vs. price of $3.47 (19.7% below fair value)
No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
59GF Score
Get the complete analysis for CMVLF
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMVLF has been successfully added to your 
